Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
RESEARCH TOOLSreports
Iovance Biotherapeutics (IOVA) Stock Price & Analysis
2,518 Followers
IOVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.21 - $18.33
Previous Close$10.24
Volume4.51M
Average Volume (3M)8.84M
Market Cap
$2.87B
Enterprise Value$2.66B
Total Cash (Recent Filing)$279.87M
Total Debt (Recent Filing)$75.86M
Price to Earnings (P/E)-5.6
Beta0.83
Next Earnings
Aug 01, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding279,832,722
10 Day Avg. Volume6,980,464
30 Day Avg. Volume8,843,975
Standard Deviation0.27
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.21
Price to Sales (P/S)5944.99
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.24K
Enterprise Value/Gross Profit-278.22
Enterprise Value/Ebitda-13.33
Forecast
1Y Price Target
$25.55Price Target Upside149.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Iovance Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst increases Amtagvi 2Q24 and FY24 sales estimates based on robust enrollment and favorable insurance coverage, signaling positive revenue prospects.
Market ExpansionIovance's plans to submit an MAA in the EU and engage with regulatory bodies in the UK and Canada hint at a strategic ex-US expansion, broadening Amtagvi's market reach.
Product AdoptionAmtagvi's addition as a preferred therapy in the NCCN guidelines for cutaneous melanoma suggests strong support within the medical community, potentially increasing its adoption.
Bears Say
Drug Safety ConcernsThe label includes a boxed warning noting risk of treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.
Financial HealthIovance reports a cash burn of $320-340 million, which is projected to fund operations until the second half of 2025.
Regulatory ChallengesFDA has put a clinical trial on partial hold following the report of a serious adverse event.
---
Ownership Overview
12.58% Insiders
16.15% Mutual Funds
51.14% Other Institutional Investors
20.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $3.21 and its highest was $18.33 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Currently, no data Available
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.424 by $0.004.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -$0.34.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 279,832,730 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.424. Following the earnings report the stock price went down -18.513%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Among the largest hedge funds holding Iovance Biotherapeutics Inc’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics Inc’s shares valued at 286M.
---
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.55 (149.51% Upside)
$25.55 (149.51% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 96%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 7.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $48.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.53%
12-Months-Change
Fundamentals
Return on Equity
-66.77%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
IOVA Earnings Call
Q1 2024
0:00 / 0:00
---
IOVA Stock 12 Month Forecast
Average Price Target
$25.55
▲(149.51% Upside)
Technical Analysis
Adverum Biotechnologies
―
Kura Oncology
―
Corvus Pharmaceuticals
―
Arcturus Therapeutics
―
Best Analysts Covering IOVA
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+15.13%
reiterated a buy rating 9 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +15.13% per trade.
---